|Bid||0.0150 x N/A|
|Ask||0.0250 x N/A|
|Day's Range||0.0000 - 0.0000|
|52 Week Range|
|Beta (5Y Monthly)||0.97|
|PE Ratio (TTM)||0.14|
|Earnings Date||Sept 30, 2022 - Oct 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Toronto, Ontario--(Newsfile Corp. - September 12, 2022) - High Fusion Inc. (CSE: FUZN) ("High Fusion" or the "Company") is pleased to announce a corporate strategy update of its partially-owned subsidiary, Neural Therapeutics Inc. ("Neural").Intellectual Property AchievementsIn partnership and collaboration with its extraction partners based in Nevada, Neural has developed a new and novel extraction methodology for full spectrum Mescaline and Mescaline isolate from the San Pedro plant. Neural ha
Toronto, Ontario--(Newsfile Corp. - August 3, 2022) - High Fusion Inc. (CSE: FUZN) ("High Fusion" or the "Company") is pleased to announce an extension of the term of the August 2018 senior secured debentures ("Debentures") from August 3, 2022 to February 3, 2023.With the extension of the maturity date of the Debentures, the interest on the debentures to maturity will increase to 24% per annum. One half of the interest on the Debentures shall ...
Toronto, Ontario--(Newsfile Corp. - July 21, 2022) - High Fusion Inc. (CSE: FUZN) ("High Fusion" or the "Company") announces that it has changed its auditors from Harbourside CPA LLP (the "Former Auditor") to BF Borgers CPA PC (the "Successor Auditor"). The Former Auditor resigned as the auditor of the Company effective July 14, 2021. The Company has appointed the Successor Auditor on July 18, 2021, until the next annual shareholders' meeting of the ...